Cargando…
The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling
BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METH...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896784/ https://www.ncbi.nlm.nih.gov/pubmed/36732752 http://dx.doi.org/10.1186/s12967-023-03917-x |
_version_ | 1784882121410609152 |
---|---|
author | Luo, Ailin Wu, Zifeng Li, Shan McReynolds, Cindy B. Wang, Di Liu, Hanyu Huang, Chaoli He, Teng Zhang, Xinying Wang, Yuanyuan Liu, Cunming Hammock, Bruce D. Hashimoto, Kenji Yang, Chun |
author_facet | Luo, Ailin Wu, Zifeng Li, Shan McReynolds, Cindy B. Wang, Di Liu, Hanyu Huang, Chaoli He, Teng Zhang, Xinying Wang, Yuanyuan Liu, Cunming Hammock, Bruce D. Hashimoto, Kenji Yang, Chun |
author_sort | Luo, Ailin |
collection | PubMed |
description | BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METHODS: According to a sucrose preference test (SPT), spared nerve injury (SNI) mice were classified into pain with or without an anhedonia phenotype. Then, sEH protein expression and inflammatory cytokines were assessed in selected tissues. Furthermore, we used sEH inhibitor TPPU to determine the role of sEH in chronic pain and depression. Importantly, agonists and antagonists of aryl hydrocarbon receptor (AHR) and translocator protein (TSPO) were used to explore the pathogenesis of sEH signaling. RESULTS: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut. Importantly, serum CYP1A1 and inflammatory cytokines, such as interleukin 1β (IL-1β) and the tumor necrosis factor α (TNF-α), were increased simultaneously. TPPU improved the scores of mechanical withdrawal threshold (MWT) and SPT, and decreased the levels of serum CYP1A1 and inflammatory cytokines. AHR antagonist relieved the anhedonia behaviors but not the algesia behaviors in anhedonia-susceptible mice, whereas an AHR agonist abolished the antidepressant-like effect of TPPU. In addition, a TSPO agonist exerted a similar therapeutic effect to that of TPPU, whereas pretreatment with a TSPO antagonist abolished the antidepressant-like and analgesic effects of TPPU. CONCLUSIONS: sEH underlies the mechanisms of the comorbidity of chronic pain and depression and that TPPU exerts a beneficial effect on anhedonia behaviors in a pain model via AHR and TSPO signaling. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03917-x. |
format | Online Article Text |
id | pubmed-9896784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98967842023-02-04 The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling Luo, Ailin Wu, Zifeng Li, Shan McReynolds, Cindy B. Wang, Di Liu, Hanyu Huang, Chaoli He, Teng Zhang, Xinying Wang, Yuanyuan Liu, Cunming Hammock, Bruce D. Hashimoto, Kenji Yang, Chun J Transl Med Research BACKGROUND: Patients suffering from chronic pain often also exhibit depression symptoms. Soluble epoxide hydrolase (sEH) inhibitors can decrease blood levels of inflammatory cytokines. However, whether inhibiting sEH signaling is beneficial for the comorbidity of pain and depression is unknown. METHODS: According to a sucrose preference test (SPT), spared nerve injury (SNI) mice were classified into pain with or without an anhedonia phenotype. Then, sEH protein expression and inflammatory cytokines were assessed in selected tissues. Furthermore, we used sEH inhibitor TPPU to determine the role of sEH in chronic pain and depression. Importantly, agonists and antagonists of aryl hydrocarbon receptor (AHR) and translocator protein (TSPO) were used to explore the pathogenesis of sEH signaling. RESULTS: In anhedonia-susceptible mice, the tissue levels of sEH were significantly increased in the medial prefrontal cortex (mPFC), hippocampus, spinal cord, liver, kidney, and gut. Importantly, serum CYP1A1 and inflammatory cytokines, such as interleukin 1β (IL-1β) and the tumor necrosis factor α (TNF-α), were increased simultaneously. TPPU improved the scores of mechanical withdrawal threshold (MWT) and SPT, and decreased the levels of serum CYP1A1 and inflammatory cytokines. AHR antagonist relieved the anhedonia behaviors but not the algesia behaviors in anhedonia-susceptible mice, whereas an AHR agonist abolished the antidepressant-like effect of TPPU. In addition, a TSPO agonist exerted a similar therapeutic effect to that of TPPU, whereas pretreatment with a TSPO antagonist abolished the antidepressant-like and analgesic effects of TPPU. CONCLUSIONS: sEH underlies the mechanisms of the comorbidity of chronic pain and depression and that TPPU exerts a beneficial effect on anhedonia behaviors in a pain model via AHR and TSPO signaling. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-03917-x. BioMed Central 2023-02-02 /pmc/articles/PMC9896784/ /pubmed/36732752 http://dx.doi.org/10.1186/s12967-023-03917-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Luo, Ailin Wu, Zifeng Li, Shan McReynolds, Cindy B. Wang, Di Liu, Hanyu Huang, Chaoli He, Teng Zhang, Xinying Wang, Yuanyuan Liu, Cunming Hammock, Bruce D. Hashimoto, Kenji Yang, Chun The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title | The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title_full | The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title_fullStr | The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title_full_unstemmed | The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title_short | The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling |
title_sort | soluble epoxide hydrolase inhibitor tppu improves comorbidity of chronic pain and depression via the ahr and tspo signaling |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896784/ https://www.ncbi.nlm.nih.gov/pubmed/36732752 http://dx.doi.org/10.1186/s12967-023-03917-x |
work_keys_str_mv | AT luoailin thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wuzifeng thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT lishan thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT mcreynoldscindyb thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wangdi thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT liuhanyu thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT huangchaoli thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT heteng thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT zhangxinying thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wangyuanyuan thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT liucunming thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT hammockbruced thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT hashimotokenji thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT yangchun thesolubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT luoailin solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wuzifeng solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT lishan solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT mcreynoldscindyb solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wangdi solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT liuhanyu solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT huangchaoli solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT heteng solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT zhangxinying solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT wangyuanyuan solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT liucunming solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT hammockbruced solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT hashimotokenji solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling AT yangchun solubleepoxidehydrolaseinhibitortppuimprovescomorbidityofchronicpainanddepressionviatheahrandtsposignaling |